William Blair initiated coverage of Contineum (CTNM) with an Outperform rating. Contineum is a clinical-stage biotech developing small-molecule therapeutics for indications in the neuroinflammation and immunology space developing PIPE-791, a wholly owned asset for the treatment of idiopathic pulmonary fibrosis, progressive forms of multiple sclerosis and chronic pain indications, notes the analyst, who sees a fair value of $23.26 per share.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTNM:
- Promising Developments at Contineum Therapeutics Signal Undervaluation and Favorable Risk-Reward
- Contineum Therapeutics Reports Q1 2025 Financial Results
- Contineum Therapeutics Files $300M Shelf Registration
- Contineum files $300M mixed securities shelf
- Contineum Therapeutics, Inc. Class A (CTNM) Q1 Earnings Cheat Sheet